Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting

Keywords

Tumor microenvironment, Immune system, Cancer immunology, Cancer, Context (archaeology)

References

• Differing Patterns of Circulating Regulatory T-Cells and Myeloid Derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF with Peptide VaccinationLake Douglas — 2012
• Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humansFrédéric Delacoux — 2013
• CTLA-4 and PD-1 PathwaysAngel Montero Bostarreche, Carmen Diéguez — 2016
• Thymic and peripheral differentiation of regulatory T cells.Hyang-Mi Lee, Jhoanne L. Bautista, Chyi‐Song Hsieh — 2011
• Phenotypic and functional characteristics of ATP-hydrolysing CD4+CD39+ FOXP3+ and CD4+CD39+FOXP3negT-cell subsets in patients with cancerPatrick J. Schuler, Bastian Schilling, Malgorzata Harasymczuk — 2012
• Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometrySaskia J. Santegoets, Eveline M. Dijkgraaf, Alessandra Battaglia — 2015
• Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approachesThomas Horn, Jessica Gräb, Julia Schusdziarra — 2013
• T-cell exhaustion in the tumor microenvironmentYuyong Jiang, Yongsheng Li, Bo Zhu — 2015
• Tissue resident regulatory T cells: novel therapeutic targets for human diseaseXiaohui Zhou, Jiayou Tang, Hao Cao — 2015
• Apoptotic tumor cells induce IL-27 release from human DC to activate regulatory T cells that express CD69 and attenuate cytotoxicityDivya Sekar, Christina Hahn, Bernhard Brüne — 2012
• Human CD4+CD39+ regulatory T cells produce adenosine upon co‐expression of surface CD73 or contact with CD73+ exosomes or CD73+ cellsPatrick J. Schuler, Zenichiro Saze, C-S Hong — 2014
• The role of regulatory T cells in cancer immunologyTheresa L. Whiteside — 2015
• 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphomaJohn E. Janik, John C. Morris, Deirdre O’Mahony — 2015
• Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumorsAlexander Pedroza‐González, Guoying Zhou, Ernesto Vargas-Méndez — 2015
• Nivolumab plus ipilimumab in the treatment of advanced melanomaKaty K. Tsai, Adil Daud — 2015
• A Transendocytosis model of CTLA-4 function predicts its suppressive behaviour on regulatory T cellsTie Zheng Hou, Omar Qureshi, Chun Jing Wang — 2015
• Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAPEyad Elkord, May Abd Al Samid, Belal Chaudhary — 2015
• CTLA-4+ Regulatory T Cells Increased in Cetuximab Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor PrognosisHyun-Bae Jie, Patrick J. Schuler, Steve Lee — 2015
• Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.Gabriela Bindea, Bernhard Mlecnik, Marie Tosolini — 2013
• Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell responsePia Kvistborg, Daisy Philips, Sander Kelderman — 2014

Cited by

• Evaluation of T‐lymphocyte subpopulations in actinic keratosis, in situ and invasive squamous cell carcinoma of the skinDaniel E. Whitney, Charles H. Fine, Geoff Parker — 2018
• Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinomaJosé Ramón López de la Osa — 2018
• Impact of Metabolism on T-Cell Differentiation and Function and Cross Talk with Tumor MicroenvironmentSoumaya Kouidhi, Amel Benammar Elgaaïed, Salem Chouaı̈b — 2017
• Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to ImmunotherapyGlen J. Weiss, Julia Beck, Donald P. Braun — 2017
• Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironmentAzharuddin Sajid Syed Khaja, Salman M. Toor, Haytham El Salhat — 2017
• Immunotherapy for colorectal cancer: where are we heading?Debora Basile, Silvio Ken Garattini, Marta Bonotto — 2017
• Heterogeneity in renal cell carcinoma.Alp Tuna Beksaç, David J. Paulucci, Kyle A. Blum — 2017
• Leukocyte trafficking in tumor microenvironment.Annalisa Del Prete, Tiziana Schioppa, Laura Tiberio — 2017
• Current Perspective on In Vivo Molecular Imaging of Immune CellsAnushree Seth, Hye‐Kyung Park, Kwan Soo Hong — 2017
• Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal CancerAzharuddin Sajid Syed Khaja, Salman M. Toor, Haytham El Salhat — 2017
• Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.Chen Liu, Cheng He, Guopei Luo — 2017
• Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomesBiyu Xu, Ting Wang — 2017
• Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment.Wanfu Lin, Jianying Lu, Bin-bin Cheng — 2017
• Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapyDan Ou, Julien Adam, Ingrid Garberis — 2017
• Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapySigrun Smola, Connie Trimble, Peter L. Stern — 2017
• High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome.Peter Hollander, Peter Kamper, Karin E. Smedby — 2017
• Stop and Go: Hematopoietic cell transplantation in the era of CAR T cell and checkpoint inhibitorsArnab Ghosh, Ioannis Politikos, Miguel‐Angel Perales — 2017
• The role and significance of VEGFR2+ regulatory T cells in tumor immunityPanrong Zhu, Chenxi Hu, Kaiyuan Hui — 2017
• A Jak2‐selective inhibitor potently reverses the immune suppression by modulating the tumor microenvironment for cancer immunotherapyWei He, Yi Zhu, Ruoyu Mu — 2017
• AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and CancerErika Jensen‐Jarolim, Heather J. Bax, Rodolfo Bianchini — 2017

Related papers

• Suppressor cells and malignancy. I. Suppressor macrophages and suppressor T cells in experimental animals.David Naor, Jonathan S. Duke‐Cohan — 1986
• Supplementary Data from Claudin-12 Deficiency Inhibits Tumor Growth by Impairing Transendothelial Migration of Myeloid-Derived Suppressor CellsHong Cao, Ni Chen, Le Han — 2023
• The First Tianjin, China Forum on Tumor MicroenvironmentEvan T. Keller, Lu-Yuan Li — 2011
• Supplementary Figure 3 from COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor CellsMitsugu Fujita, Gary Kohanbash, Wendy Fellows-Mayle — 2023
• Supplementary Figure 7 from The Inflammasome Component Nlrp3 Impairs Antitumor Vaccine by Enhancing the Accumulation of Tumor-Associated Myeloid-Derived Suppressor CellsHendrik W. van Deventer, Joseph E. Burgents, Qing Ping Wu — 2023
• Tumor microenvironment components: Allies of cancer progression.Pablo Igor Ribeiro Franco, Arthur Perillo Rodrigues, Liliana Borges de Menezes — 2019
• Myeloid-Derived Suppressor Cells in Some Oncohematological DiseasesА. V. Ponomarev — 2017
• Role of the tumor microenvironment in tumor progression and the clinical applications (Review).Yao Yuan, Yuchen Jiang, Chongkui Sun — 2016
• PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progressionLufei Sui, Suming Wang, Debolina Ganguly — 2022